Report Detail
Global Short-acting B2 Agonists Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
- RnM4524146 |
- 17 March, 2023 |
- Global |
- 93 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Short-acting B2 Agonists market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Short-acting B2 agonists (SABAs) are albuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm caused by COPD, bronchial asthma, or emphysema.
This report is a detailed and comprehensive analysis for global Short-acting B2 Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Short-acting B2 Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Short-acting B2 Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Short-acting B2 Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Short-acting B2 Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Short-acting B2 Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Short-acting B2 Agonists market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer AG, Teva, Roche, Viatris and GSK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Short-acting B2 Agonists market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Albuterol
Metaproterenol
Levalbuterol
Other
Market segment by Application
COPD
Asthma
Other
Major players covered
Bayer AG
Teva
Roche
Viatris
GSK
Cipla Limited
Johnson & Johnson
Merck
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Short-acting B2 Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Short-acting B2 Agonists, with price, sales, revenue and global market share of Short-acting B2 Agonists from 2018 to 2023.
Chapter 3, the Short-acting B2 Agonists competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Short-acting B2 Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Short-acting B2 Agonists market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Short-acting B2 Agonists.
Chapter 14 and 15, to describe Short-acting B2 Agonists sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope of Short-acting B2 Agonists
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Short-acting B2 Agonists Consumption Value by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 Albuterol
- 1.3.3 Metaproterenol
- 1.3.4 Levalbuterol
- 1.3.5 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Short-acting B2 Agonists Consumption Value by Application: 2018 Versus 2022 Versus 2029
- 1.4.2 COPD
- 1.4.3 Asthma
- 1.4.4 Other
- 1.5 Global Short-acting B2 Agonists Market Size & Forecast
- 1.5.1 Global Short-acting B2 Agonists Consumption Value (2018 & 2022 & 2029)
- 1.5.2 Global Short-acting B2 Agonists Sales Quantity (2018-2029)
- 1.5.3 Global Short-acting B2 Agonists Average Price (2018-2029)
2 Manufacturers Profiles
- 2.1 Bayer AG
- 2.1.1 Bayer AG Details
- 2.1.2 Bayer AG Major Business
- 2.1.3 Bayer AG Short-acting B2 Agonists Product and Services
- 2.1.4 Bayer AG Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 Bayer AG Recent Developments/Updates
- 2.2 Teva
- 2.2.1 Teva Details
- 2.2.2 Teva Major Business
- 2.2.3 Teva Short-acting B2 Agonists Product and Services
- 2.2.4 Teva Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.2.5 Teva Recent Developments/Updates
- 2.3 Roche
- 2.3.1 Roche Details
- 2.3.2 Roche Major Business
- 2.3.3 Roche Short-acting B2 Agonists Product and Services
- 2.3.4 Roche Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.3.5 Roche Recent Developments/Updates
- 2.4 Viatris
- 2.4.1 Viatris Details
- 2.4.2 Viatris Major Business
- 2.4.3 Viatris Short-acting B2 Agonists Product and Services
- 2.4.4 Viatris Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.4.5 Viatris Recent Developments/Updates
- 2.5 GSK
- 2.5.1 GSK Details
- 2.5.2 GSK Major Business
- 2.5.3 GSK Short-acting B2 Agonists Product and Services
- 2.5.4 GSK Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 GSK Recent Developments/Updates
- 2.6 Cipla Limited
- 2.6.1 Cipla Limited Details
- 2.6.2 Cipla Limited Major Business
- 2.6.3 Cipla Limited Short-acting B2 Agonists Product and Services
- 2.6.4 Cipla Limited Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.6.5 Cipla Limited Recent Developments/Updates
- 2.7 Johnson & Johnson
- 2.7.1 Johnson & Johnson Details
- 2.7.2 Johnson & Johnson Major Business
- 2.7.3 Johnson & Johnson Short-acting B2 Agonists Product and Services
- 2.7.4 Johnson & Johnson Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.7.5 Johnson & Johnson Recent Developments/Updates
- 2.8 Merck
- 2.8.1 Merck Details
- 2.8.2 Merck Major Business
- 2.8.3 Merck Short-acting B2 Agonists Product and Services
- 2.8.4 Merck Short-acting B2 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.8.5 Merck Recent Developments/Updates
3 Competitive Environment: Short-acting B2 Agonists by Manufacturer
- 3.1 Global Short-acting B2 Agonists Sales Quantity by Manufacturer (2018-2023)
- 3.2 Global Short-acting B2 Agonists Revenue by Manufacturer (2018-2023)
- 3.3 Global Short-acting B2 Agonists Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)
- 3.4.1 Producer Shipments of Short-acting B2 Agonists by Manufacturer Revenue ($MM) and Market Share (%): 2022
- 3.4.2 Top 3 Short-acting B2 Agonists Manufacturer Market Share in 2022
- 3.4.2 Top 6 Short-acting B2 Agonists Manufacturer Market Share in 2022
- 3.5 Short-acting B2 Agonists Market: Overall Company Footprint Analysis
- 3.5.1 Short-acting B2 Agonists Market: Region Footprint
- 3.5.2 Short-acting B2 Agonists Market: Company Product Type Footprint
- 3.5.3 Short-acting B2 Agonists Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Short-acting B2 Agonists Market Size by Region
- 4.1.1 Global Short-acting B2 Agonists Sales Quantity by Region (2018-2029)
- 4.1.2 Global Short-acting B2 Agonists Consumption Value by Region (2018-2029)
- 4.1.3 Global Short-acting B2 Agonists Average Price by Region (2018-2029)
- 4.2 North America Short-acting B2 Agonists Consumption Value (2018-2029)
- 4.3 Europe Short-acting B2 Agonists Consumption Value (2018-2029)
- 4.4 Asia-Pacific Short-acting B2 Agonists Consumption Value (2018-2029)
- 4.5 South America Short-acting B2 Agonists Consumption Value (2018-2029)
- 4.6 Middle East and Africa Short-acting B2 Agonists Consumption Value (2018-2029)
5 Market Segment by Type
- 5.1 Global Short-acting B2 Agonists Sales Quantity by Type (2018-2029)
- 5.2 Global Short-acting B2 Agonists Consumption Value by Type (2018-2029)
- 5.3 Global Short-acting B2 Agonists Average Price by Type (2018-2029)
6 Market Segment by Application
- 6.1 Global Short-acting B2 Agonists Sales Quantity by Application (2018-2029)
- 6.2 Global Short-acting B2 Agonists Consumption Value by Application (2018-2029)
- 6.3 Global Short-acting B2 Agonists Average Price by Application (2018-2029)
7 North America
- 7.1 North America Short-acting B2 Agonists Sales Quantity by Type (2018-2029)
- 7.2 North America Short-acting B2 Agonists Sales Quantity by Application (2018-2029)
- 7.3 North America Short-acting B2 Agonists Market Size by Country
- 7.3.1 North America Short-acting B2 Agonists Sales Quantity by Country (2018-2029)
- 7.3.2 North America Short-acting B2 Agonists Consumption Value by Country (2018-2029)
- 7.3.3 United States Market Size and Forecast (2018-2029)
- 7.3.4 Canada Market Size and Forecast (2018-2029)
- 7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
- 8.1 Europe Short-acting B2 Agonists Sales Quantity by Type (2018-2029)
- 8.2 Europe Short-acting B2 Agonists Sales Quantity by Application (2018-2029)
- 8.3 Europe Short-acting B2 Agonists Market Size by Country
- 8.3.1 Europe Short-acting B2 Agonists Sales Quantity by Country (2018-2029)
- 8.3.2 Europe Short-acting B2 Agonists Consumption Value by Country (2018-2029)
- 8.3.3 Germany Market Size and Forecast (2018-2029)
- 8.3.4 France Market Size and Forecast (2018-2029)
- 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
- 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
- 9.1 Asia-Pacific Short-acting B2 Agonists Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific Short-acting B2 Agonists Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific Short-acting B2 Agonists Market Size by Region
- 9.3.1 Asia-Pacific Short-acting B2 Agonists Sales Quantity by Region (2018-2029)
- 9.3.2 Asia-Pacific Short-acting B2 Agonists Consumption Value by Region (2018-2029)
- 9.3.3 China Market Size and Forecast (2018-2029)
- 9.3.4 Japan Market Size and Forecast (2018-2029)
- 9.3.5 Korea Market Size and Forecast (2018-2029)
- 9.3.6 India Market Size and Forecast (2018-2029)
- 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
- 9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
- 10.1 South America Short-acting B2 Agonists Sales Quantity by Type (2018-2029)
- 10.2 South America Short-acting B2 Agonists Sales Quantity by Application (2018-2029)
- 10.3 South America Short-acting B2 Agonists Market Size by Country
- 10.3.1 South America Short-acting B2 Agonists Sales Quantity by Country (2018-2029)
- 10.3.2 South America Short-acting B2 Agonists Consumption Value by Country (2018-2029)
- 10.3.3 Brazil Market Size and Forecast (2018-2029)
- 10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
- 11.1 Middle East & Africa Short-acting B2 Agonists Sales Quantity by Type (2018-2029)
- 11.2 Middle East & Africa Short-acting B2 Agonists Sales Quantity by Application (2018-2029)
- 11.3 Middle East & Africa Short-acting B2 Agonists Market Size by Country
- 11.3.1 Middle East & Africa Short-acting B2 Agonists Sales Quantity by Country (2018-2029)
- 11.3.2 Middle East & Africa Short-acting B2 Agonists Consumption Value by Country (2018-2029)
- 11.3.3 Turkey Market Size and Forecast (2018-2029)
- 11.3.4 Egypt Market Size and Forecast (2018-2029)
- 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
- 11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
- 12.1 Short-acting B2 Agonists Market Drivers
- 12.2 Short-acting B2 Agonists Market Restraints
- 12.3 Short-acting B2 Agonists Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
- 12.5.1 Influence of COVID-19
- 12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
- 13.1 Raw Material of Short-acting B2 Agonists and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Short-acting B2 Agonists
- 13.3 Short-acting B2 Agonists Production Process
- 13.4 Short-acting B2 Agonists Industrial Chain
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Short-acting B2 Agonists Typical Distributors
- 14.3 Short-acting B2 Agonists Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Short-acting B2 Agonists. Industry analysis & Market Report on Short-acting B2 Agonists is a syndicated market report, published as Global Short-acting B2 Agonists Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Short-acting B2 Agonists market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
